![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
克罗瓦利马布:首次获得批准
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|May 13, 2024
概括
克罗瓦利马布 (Crovalimab) 是一种抗补剂C5抗体,为阳性夜间血红蛋白尿症 (PNH) 提供了一种新的治疗方法. 它独特的回收机制允许每月进行皮下注射,提高患者的便利性和护理.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
背景情况:
- 补充成分C5 (C5) 在补充介导疾病中起着至关重要的作用.
- 透性夜间血红蛋白尿 (PNH) 是一种罕见的血液疾病,其特征是补充介导的血管内血解.
- 现有的PNH治疗方法通常需要频繁的注射或静脉注射.
研究的目的:
- 总结一下crovalimab的发展里程碑.
- 值得一提的是,克罗瓦利马布在中国首次被批准用于治疗阳性夜间血红蛋白尿症 (PNH).
- 讨论crovalimab作为补充介导疾病的新疗法的潜力.
主要方法:
- 克罗瓦利马布是一种人性化的,反C5循环单克隆抗体.
- 它准C5,抑制其裂变并阻断终端补体通路.
- 抗体的设计允许持续的补充抑制和每月一次的皮下注射.
主要成果:
- 克罗瓦利马布于2024年2月在中国首次获得批准,用于青少年和成人 (≥12岁) 的PNH治疗.
- 它随后于2024年3月在日本批准用于PNH,包括以前未接受治疗的患者和以前接受过治疗的患者.
- 美国和欧盟正在进行PNH治疗的监管审查.
结论:
- 克罗瓦利马布代表了PNH治疗的重大进展.
- 它方便的剂量方案和持续的疗效提供了一个有前途的治疗选择.
- 该药物的发展里程碑为更广泛地获得PNH治疗铺平了道路.
更多相关视频
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158